Kornimate/medical-research-clean huggingface dataset:
study incidence and characteristics of malignant neoplasies in patients with hemoglobinopathy followed in italy

Conditions: Malignacy, Hemoglobinopathie

Summary: the trial aims to increase the information available on the relevance of tumor pathology in hemoglobinopathies, updating the data relating to hepatocarcinoma and investigating which other tumors are more frequent in patients with hemoglobinopathies. still, in relation to tumor pathology, the study will evaluate any differences between the different types of hemoglobinopathy and will investigate the association between the appearance of neoplasms and risk factors such as age, sex, iron accumulation markers, history of bone marrow transplant, and others.

by providing targeted screening strategies, these data may contribute to the early identification of tumor pathology in hemoglobinopathies, and, by contributing to the identification of risk factors, to its prevention. they will also be able to contribute to understanding which therapeutic approaches in the case of cancer are most appropriate in this category of subjects. to be able to go even deeper into understanding the possible link that exists between tumors and hemoglobinopathy, a further data collection (substudy) has been prepared in which additional and more detailed information will be collected in order to evaluate which is the percentage of patients who develop tumors compared to all those with hemoglobinopathy. the risk of developing tumors will also be assessed for each hemoglobinopathy (transfusion-dependent beta-thalassemia, transfusion independent beta-thalassemia, hemoglobin h disease, sickle cell disease, microdrepanocytosis)

Eligibility criteria:
inclusion criteria: * transfusion-dependent or independent beta-thalassemia, hemoglobin h disease, sickle cell anemia and microdrepanocytosis * current or previous malignant tumor pathology * availability of medical history including the most relevant clinical and instrumental data before the onset of cancer exclusion criteria: * - other haematological diseases other than hemoglobinopathies * absence of neoplastic events in the clinical history * non-availability of relevant clinical and instrumental data
a small changes weight loss program and message dissemination via facebook in chicago's west side

Conditions: Obesity

Summary: african-american communities experience a greater burden of obesity-related diseases such as type 2 diabetes mellitus and cardiovascular disease and higher rates of obesity, compared to other race groups. there is a need for interventions that show promise in mitigating these disparities. the primary goal of this project is to pilot test whether an existing "small-changes" intervention for weight loss can be modified and delivered within the west side alive churches.


Eligibility criteria:
inclusion criteria: 1. bmi 25-45 kg/m2 2. age 18-75 3. attend one of the west side partnership churches at least 2 times per month 4. able to attend in-person meetings 5. willing to share their experiences on the west side alive facebook page exclusion criteria: 1. blood pressure \> 170/90 (self-report or during the wsa screening) 2. diabetes treated with insulin 3. history of cancer within the past 5 years 4. pregnancy or breastfeeding in the last 6 months, planning to become pregnant in the next 3 months
pulmonary function in patients with hodgkin's disease receiving bleomycin-based chemotherapy

Conditions: Hodgkin's Disease

Summary: the purpose of this study is to find out the impact bleomycin-containing chemotherapy, given with or without chest radiation therapy, on patients' lung function over time.

* the tests and procedures in this study are part of regular cancer care but this study offers more structured timing of these standard tests. * due to the potential lung toxicity associated with bleomycin-based chemotherapy, pulmonary function tests are routinely performed. pulmonary function tests will be performed by a licensed, registered respiratory therapist and performed prior to the beginning of treatment, between the chemotherapy and radiation therapy (only for patients receiving both chemotherapy and radiation therapy), and at approximately 1 month, 6 months, 1 year and 2 years after the completion of all treatments. * a cat scan will be performed prior to the beginning of treatment, and approximately 1 month, 6 months, 1 year and 2 years after the completion of all treatments. * a self-administered questionnaire will be performed on the days the patient is undergoing pulmonary function tests.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed classical hodgkin's disease, with mediastinal involvement * bleomycin-based chemotherapy alone or in combination with mediastinal irradiation exclusion criteria: * prior chest irradiation * mediastinal irradiation received at an outside institution * refractory or progressive disease on treatment

Keywords: pulmonary function bleomycin-based chemotherapy mediastinal irradiation
impact of breathing exercises and meditation on reducing stress and improving quality of life of glaucoma patients: an electronic pilot feasibility study

Conditions: Glaucoma; Stress; Quality of Life

Summary: the goal of this electronic feasibility clinical trial study is to evaluate the effects of breathing and meditation techniques on stress levels in patients with glaucoma. the main questions it aims to answer are: * does breathing and meditation decrease the level of stress in glaucoma patients? * does breathing and meditation improve disease specific quality of life in glaucoma patients * does breathing and meditation affect the importance that in glaucoma patients place on future consequences? participants will participate in online session where they will be taught proper breathing and meditation technique to practice. they will also be completing online questionnaires following independent practice sessions over time. researchers will compare the breathing and meditation group to the usual care group to see if the outcomes are different.


Eligibility criteria:
inclusion criteria: patients diagnosed with glaucoma. being able to provide valid informed consent to participate in the research study. patients aged 40-65. being able to read and understand english. having no significant self-reported or physician-diagnosed mental health disorder. independent access to a computer to participate in virtual sessions. must be able to sit comfortably for 30-35 minutes without any major pain or discomfort, can hear well enough to follow verbal instructions when the eyes are closed, and be in good general physical health. exclusion criteria: inability to provide valid informed consent. significant communication barriers or lack of english proficiency that prevents participants from completing the questionnaires. having a lifetime diagnosis of self-reported other serious mental disorders, including bipolar i or ii disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder). self-reported substance abuse or dependence within the past 3 months. having acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months. having irreversible vision loss that prevents one from completing the questionnaires. participation in a study involving similar techniques.

Keywords: glaucoma breathing meditation stress quality of life future consequences
stepped care for posttraumatic stress disorder study

Conditions: Post Traumatic Stress Disorder

Summary: posttraumatic stress disorder (ptsd) prevalence can be as high as 50% in low income and racially diverse primary care clinics, wherein only 13% of people with ptsd receive any treatment. this study extends a program of research by the investigator focused on developing adaptive interventions for ptsd. the adaptive intervention sequences a digital mental health intervention (dmhi) and brief trauma- and skills-focused treatments for ptsd. the selected treatments are brief and scalable, less burdensome to systems of care, and highly acceptable to diverse patients and care settings. these treatments are: web-administered skills training in affective and interpersonal regulation (webstair), brief stair, and written exposure therapy (wet).

this study uses a sequential, multiple assignment, randomized trial (smart) design. all participants enrolled will receive access to webstair at baseline ("initial treatment"). nonresponders at 4 weeks are randomized to either continue webstair or webstair plus community health worker coaching ("stage 1 treatments"). nonresponders at 8 weeks are re-randomized to clinician-administered treatments, either brief stair or wet ("stage 2 treatments"). nonresponse is defined as less than a 15-point decrease in ptsd symptom severity, as measured by the ptsd checklist for dsm-5 (pcl-5). the objectives of this study are to: * examine the main effects of stage 1 treatments, stage 2 treatments, and embedded * adaptive interventions on ptsd symptom severity. * confirm mechanisms of change established in the extant ptsd literature * identify patient-level moderators of change in ptsd symptoms severity at 18 weeks

Eligibility criteria:
inclusion criteria: assessed at pre-screening * boston medical center primary care patient * at least 18 years of age * access to computer or mobile device * able to receive treatments in english or spanish * able to read at 4th grade level assessed at baseline * endorsement of criterion a trauma using the life events checklist for the dsm-5 (lec-5), assessed at baseline * ptsd diagnosis, confirmed by the clinician-administered ptsd scale for the dsm-5 (caps-5) assessed at baseline * clinically appropriate for outpatient level of care * stable on psychotropic medication for \>4 weeks exclusion criteria: assessed at pre-screening • patient is currently engaged in clinician-administered therapy assessed at baseline (clinician interview) * patient is not clinically appropriate for outpatient level of care. * acute risk for suicidal thoughts or behaviors, assessed by the columbia suicide severity rating scale, administered by research clinician at baseline.

Keywords: stepped care skills training in affective and interpersonal regulation (stair) digital mental health intervention written exposure therapy (wet) adaptive interventions
impact of nerve-sparing radical hysterectomy on patients' urinary dynamics

Conditions: Cervical Cancer; Urinary Retention

Summary: background: radical hysterectomy is an important therapy for early cervical cancer. disfunction of urinary dynamics is the most common postoperative adverse effects, which had negative impact on patients' quality of life. nerve sparing radical hysterectomy (nsrh) could reserve inferior hypogastric plexus (ihp) innervating bladder, hence improving postoperative urinary dynamics. furthermore impact of different energy instruments on urinary dynamic isn't clear. objectives: this study is to compare urinary dynamics before and after nsrh, and to analyze the difference between biclamp forcep (biclamp® forcep, erbe elektromedizin, gmbh, tuebingen, germany) and water jet (erbejet®2) about the effects of dissecting ihp. study population: cervical cancer of figo ib stage, among which 120 cases are enrolled to randomly allocated to biclamp group or water jet group. intervention: patients accept nsrh which all will be accomplished by professor ming wu. methods: all surgical patients are accessed via urinary dynamics before and four months after nsrh. on the 14th day after surgeries, urinary catheter will be removed and residual urine volume (ruv) will be measured. for patients of ruv \> 100 ml, urinary catheter will be replaced. primary study endpoint: the successful rate of removing urinary catheter on the 14th day after nsrh. secondary study endpoint: urinary dynamics four months after nsrh.


Eligibility criteria:
inclusion criteria: * figo stage ib * asa score 0-2 exclusion criteria: * radiotherapy or chemotherapy before surgeries * asa score \> 2 * with abnormal urinary dynamics before surgeries
a study of abt-751 in patients with colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of the study is to determine if abt-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. patients will receive abt-751 by mouth daily for 21 days. patients will be off drug for 7 days before starting the next cycle of drug.


Eligibility criteria:
inclusion criteria * colorectal cancer. * recurrent tumor following treatment with irinotecan and/or oxaliplatin. * able to tolerate normal activities of daily living. * adequate bone marrow, kidney, and liver function. exclusion criteria * pregnant or breast feeding. * anti-tumor therapy within 4 weeks of the start of abt-751 administration. * prior radiation therapy. * cns metastasis.
effect of probiotic on oral health of children

Conditions: Oral Disease

Summary: the aim of the randomized, double-blind clinical trial with placebo is to answer the clinical question , or in children with diagnosed childhood early caries the use of l.salivarius and cranberry contained in nutropharma lozenges will reduce new carious lesions and reduce the titre of the carcinogenic bacteria streptococcus mutans, compared to the control group in which the placebo will be administered? the main end point will be to reduce the titre of cariogenic bacteria.

probiotic bacteria are used in the prevention and treatment of gastrointestinal diseases and infections, including the treatment of oral diseases. probiotic bacteria can be found in saliva, plaque and adhering directly to the mucous membrane. they compete with cariogenic bacteria and pathogens of periodontal disease. increased interest in probiotics means that attempts are being made to find new solutions regarding the methods of their administration. the use of probiotic bacteria brings beneficial health effects. lactobacillus salivarius is a strain isolated from human milk. it is inactive (heat treatment) and therefore does not produce metabolites that can promote the formation of carious lesions in the mouth by lowering the mouth potential of hydrogen.

Eligibility criteria:
inclusion criteria: * generally healthy children aged 3-6; * recognized caries of early childhood, dmf\> 1, * lack of active caries and inflammation of the mouth * colony forming unit cfu \> 105 / ml streptococcus mutans * a minimum of one-month period from: the last antibiotic therapy, probiotic use, professional fluoride prophylaxis or supervised tooth brushing with fluoride preparations, the use of fluoride toothpaste, not using xylitol, written consent of parents / legal guardians for participation in research. exclusion criteria: * chronic diseases and chronically taken medicines in the past, * planned change of residence during the year, * age below 3 and above 6 years, * healthy teeth, dmf = 0, * colony forming unit cfu \<105 / ml streptococcus mutans * patient during antibiotic therapy, probiotic use, professional fluoride prophylaxis or supervised tooth brushing with fluoride preparations * no toothpaste with fluoride * using xylitol * lack of written consent of parents / legal guardians for participation in research.

Keywords: probiotic oral health children
puraply™ antimicrobial wound matrix and wound management

Conditions: Pressure Ulcer; Venous Ulcer; Diabetic Ulcer; Surgical Wound; Trauma Wound

Summary: the puraply antimicrobial wound matrix (puraply am) case series is a prospective, observational study for patients who have received puraply am which consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (phmb) and is intended for the management of wounds; no experimental intervention is involved.

the purpose of the case series is to assess the ability of puraply am to meet wound specific treatment goals including management of bioburden, support of granulation tissue formation and support of wound closure. patients will undergo clinical assessments and receive the standard of care as determined by the treating physician. the case series is being undertaken to better understand puraply am utilization and subsequent healing outcomes as well as to evaluate the effects of concomitant wound therapy on healing. patient's participation may involve follow-up for up to 12 weeks following application of puraply am.

Eligibility criteria:
inclusion criteria: 1. participant is at least 18 years of age 2. participant has read, understood and signed and institutional review board (irb) approved informed consent form (icf). 3. participant has at least 1 wound appropriate for receiving puraply am, including * partial and full-thickness wounds * pressure ulcers * venous ulcers * diabetic ulcers * chronic vascular ulcers * tunneled/undermined wounds * surgical wounds (donor sites/grafts, post-mohs' surgery, post-laser surgery, podiatric, wound dehiscence) h. trauma wounds (abrasions, lacerations, second-degree burns, skin tears) i. draining wounds exclusion criteria: 1. participant has a known sensitivity to porcine materials 2. participant has a third-degree burn 3. participant has a known sensitivity to polyhexamethylenbiguanide hydrochloride (phmb) 4. participants receiving concurrent treatment with other topical antimicrobials or skin substitute products

Keywords: chronic wounds acute wounds phmb wound management bioburden collagen
qiastat-dx® meningitis/encephalitis panel performance evaluation study 001

Conditions: Meningitis/Encephalitis

Summary: study for performance evaluation of the qiastat-dx® meningitis/encephalitis panel in comparison with other chosen comparator methods.

this multicenter study aims to evaluate the performance of qiastat-dx meningitis/encephalitis (me) panel with another validated comparator method.

Eligibility criteria:
inclusion criteria: * residual specimens of csf obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis following completion of routine testing * specimen that had not been centrifuged adequate residual volume (≥400 μl) exclusion criteria: * specimens not fitting criteria outlined above * csf obtained from an external ventricular drain or shunt source * lack of clear subject identification or label on residual banked csf specimen * obvious physical damage of banked residual specimen * repeat specimens from the same subject
pericarditis: auto-inflammation in recurrent disease

Conditions: Idiopathic Recurrent Pericarditis

Summary: pericarditis is swelling of the sac that surrounds the heart, the pericardium, causing chest pain. for most patients, the condition improves with simple anti-inflammatory medications like colchicine and ibuprofen. however, in 20-30% of patients the condition comes back. diagnosis of recurrent pericarditis is frequently missed or delayed, and many patients require prolonged courses of corticosteroids to control their disease. together these factors damage the quality of life of patients with recurrent pericarditis. currently there is limited understanding of why pericarditis comes back in some patients, and how best to treat it when it does. paired (pericarditis: auto-inflammation in recurrent disease) is an observational research study funded by the british heart foundation that will investigate the role inflammation plays in recurrent pericarditis. patients with recurrent pericarditis and other auto-inflammatory diseases will be recruited from the specialist fever clinic at the royal free hospital, where they will be asked to donate blood up to six times over a three year period. healthy participants will be recruited at the royal free hospital or guy's hospital. relatives of participants with recurrent pericarditis will be recruited at the royal free hospital. they latter two groups will attend one appointment where blood or saliva samples will be taken. a subset of participants will also provide fingerstick blood samples and questionnaires from home, for up to one year. clinical data will be collected prospectively and by retrospective case note review. blood from participants will be analysed to look at how the immune cells of patients with recurrent pericarditis function during the course of their disease, and to look for genetic changes in patients with recurrent pericarditis that might contribute to their condition. together this knowledge has to potential to help clinicians diagnose and monitor patients with recurrent pericarditis more accurately, and researchers to design more effective treatments.


Eligibility criteria:
inclusion criteria: recurrent pericarditis (rp) cases: 1. patients with rp, diagnosed by a clinician, meeting the european society of cardiology (esc) diagnostic criteria. 2. where the aetiology of the rp is defined as idiopathic (i.e. there is no other aetiology identified, such as infective, malignant, post cardiac injury, as part of an autoimmune condition, as part of another known auto-inflammatory disease). relatives of rp cases: first degree relatives of participants meeting the criteria for, and included in the study as, rp cases. disease controls: patients with a systemic auto-inflammatory disease, diagnosed by a trained specialist. healthy controls: sex, ethnicity and aged matched healthy individuals who do not have a personal history of pericarditis or systemic auto-inflammatory disease. exclusion criteria: 1. individuals under 12 years of age 2. adults who are unable to give written informed consent 3. individuals who have received a blood transfusion within 4 weeks
liquid biopsy-based early detection of ovarian cancer: a proof-of-concept study ( profound-oc )

Conditions: Ovarian Cancer

Summary: this study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from newly diagnosed ovarian cancer.

peripheral blood samples from ovarian cancer (oc) patients will be prospectively collected to identify cancer-specific circulating signals by analyzing cell free dna. based on the comprehensive molecular profiling, a machine learning-driven noninvasive test will be trained and validated through a two-stage approach in clinically annotated individuals. approximately 168 stage i-ii oc patients will be enrolled in this study. age-matched female controls included in model development were recruited in another study, which are volunteers without a cancer diagnosis after routine medical screening.

Eligibility criteria:
inclusion criteria: * 40-75 years old * clinically and/or pathologically diagnosed ovarian cancer * no prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc. * able to provide a written informed consent and willing to comply with all part of the protocol procedures exclusion criteria: * pregnancy or lactating women * known prior or current diagnosis of other types of malignancies comorbidities * severe acute infection (e.g. severe or critical covid-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.0 °c) within 14 days prior to blood draw * recipients of organ transplant or prior bone marrow transplant or stem cell transplant * recipients of blood transfusion within 30 days prior to study blood draw * recipients of therapy in past 14 days prior to blood draw, including oral or iv antibiotics, glucocorticoid, azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide * other conditions that the investigators considered are not suitable for the enrollment